Nebenwirkungen · Aranesp
Aranesp 10 micrograms solution for injection in pre-filled syringe. Aranesp 15 micrograms solution for injection in pre-filled syringe. Aranesp 20 micrograms solution for injection in pre-filled syringe. Aranesp 30 micrograms solution for injection in pre-filled syringe. Aranesp 40 micrograms solution for injection in pre-filled syringe. Aranesp 50 micrograms solution for injection in pre-filled syringe. Aranesp 60 micrograms solution for injection in pre-filled syringe. Aranesp 80 micrograms solution for injection in pre-filled syringe. Aranesp 100 micrograms solution for injection in pre-filled syringe. Aranesp 130 micrograms solution for injection in pre-filled syringe. Aranesp 150 micrograms solution for injection in pre-filled syringe. Aranesp 300 micrograms solution for injection in pre-filled syringe. Aranesp 500 micrograms solution for injection in pre-filled syringe. Aranesp 10 micrograms solution for injection in pre-filled pen. Aranesp 15 micrograms solution for injection in pre-filled pen. Aranesp 20 micrograms solution for injection in pre-filled pen. Aranesp 30 micrograms solution for injection in pre-filled pen. Aranesp 40 micrograms solution for injection in pre-filled pen. Aranesp 50 micrograms solution for injection in pre-filled pen. Aranesp 60 micrograms solution for injection in pre-filled pen. Aranesp 80 micrograms solution for injection in pre-filled pen. Aranesp 100 micrograms solution for injection in pre-filled pen. Aranesp 130 micrograms solution for injection in pre-filled pen. Aranesp 150 micrograms solution for injection in pre-filled pen. Aranesp 300 micrograms solution for injection in pre-filled pen. Aranesp 500 micrograms solution for injection in pre-filled pen. Aranesp 25 micrograms solution for injection in vial. Aranesp 40 micrograms solution for injection in vial. Aranesp 60 micrograms solution for injection in vial. Aranesp 100 micrograms solution for injection in vial. Aranesp 200 micrograms solution for injection in vial. Aranesp 300 micrograms solution for injection in vial. · Abschnitt 4.8 · PDF-Seite 12
HOS-091580 · Präparat HOS-084365
Incidence of adverse reactions from controlled clinical studies and post-marketing experience are:
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-13T14:02:00Z · SHA-256 710297507186d4d2a5521d37f2bb6be5356d24770867b5c705e8fd2217fa7444 · Passage 75736041528a7e4ba2b698c7aeae93fc2bbd6bfd93f6461c57559491c53b94c6 · Zeichen 1371–1469 im Abschnitt